What is Leerink Partnrs' Estimate for MREO Q1 Earnings?

Key Points

• Leerink Partners predicts that Mereo BioPharma Group will report Q1 2026 earnings of ($0.01) per share, with full-year earnings expected at ($0.03) per share.
• Mereo BioPharma's stock was recently downgraded from a "hold" to a "sell" rating by Wall Street Zen, while Needham & Company maintains a "buy" rating with a target price of $5.00.
• The company's stock trades at around $1.68, with a market cap of $266.33 million, reflecting a fluctuation from a 12-month low of $1.47 to a high of $5.02.

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO - Free Report) - Analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for shares of Mereo BioPharma Group in a research note issued to investors on Tuesday, August 12th. Leerink Partnrs analyst J. Schwartz expects that the company will post earnings per share of ($0.01) for the quarter. The consensus estimate for Mereo BioPharma Group's current full-year earnings is ($0.03) per share. Leerink Partnrs also issued estimates for Mereo BioPharma Group's Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.04 EPS and FY2027 earnings at $0.03 EPS.

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The firm had revenue of $0.50 million for the quarter, compared to analyst estimates of $7.80 million.

Several other research analysts have also recently commented on the company. Wall Street Zen raised Mereo BioPharma Group from a "sell" rating to a "hold" rating in a research note on Saturday. Needham & Company LLC set a $5.00 price objective on Mereo BioPharma Group and gave the stock a "buy" rating in a research report on Thursday, July 10th. One investment analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the stock. According to MarketBeat, Mereo BioPharma Group currently has an average rating of "Buy" and a consensus target price of $7.20.

Mereo BioPharma Group Stock Down 2.7%

Mereo BioPharma Group stock traded down $0.0450 during mid-day trading on Thursday, reaching $1.6350. 730,252 shares of the company's stock were exchanged, compared to its average volume of 1,750,658. The company has a market cap of $259.97 million, a P/E ratio of -23.36 and a beta of 0.47. Mereo BioPharma Group has a twelve month low of $1.47 and a twelve month high of $5.02. The company has a fifty day moving average of $2.18 and a 200-day moving average of $2.36.

Institutional Trading of Mereo BioPharma Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MREO. Janus Henderson Group PLC boosted its holdings in shares of Mereo BioPharma Group by 38.7% in the 4th quarter. Janus Henderson Group PLC now owns 17,122,563 shares of the company's stock valued at $59,843,000 after buying an additional 4,776,697 shares in the last quarter. Rock Springs Capital Management LP increased its position in Mereo BioPharma Group by 0.7% during the fourth quarter. Rock Springs Capital Management LP now owns 9,599,170 shares of the company's stock worth $33,597,000 after buying an additional 65,000 shares during the period. Frazier Life Sciences Management L.P. lifted its stake in Mereo BioPharma Group by 20.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 9,440,112 shares of the company's stock valued at $25,583,000 after buying an additional 1,620,249 shares during the last quarter. 683 Capital Management LLC boosted its holdings in shares of Mereo BioPharma Group by 1.9% in the first quarter. 683 Capital Management LLC now owns 4,635,000 shares of the company's stock valued at $10,429,000 after acquiring an additional 85,000 shares during the period. Finally, Aberdeen Group plc grew its position in shares of Mereo BioPharma Group by 38.4% during the second quarter. Aberdeen Group plc now owns 3,028,872 shares of the company's stock worth $8,208,000 after acquiring an additional 840,518 shares during the last quarter. Institutional investors and hedge funds own 62.83% of the company's stock.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.